Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis.
Document Type
Journal Article
Publication Date
6-1-2016
Journal
Advances in Therapy
DOI
10.1007/s12325-016-0353-2
APA Citation
Krueger, J., Kircik, L., Hougeir, F., Friedman, A., You, X., Lucas, N., Greenberg, S., Sweetser, M., Castro-Borrero, W., McCroskery, P., & Elkins, J. (2016). Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis.. Advances in Therapy, (). http://dx.doi.org/10.1007/s12325-016-0353-2
Peer Reviewed
1